We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Enhancement Medical Warned Over Audits, Supplier Evaluations

Enhancement Medical Warned Over Audits, Supplier Evaluations

July 4, 2014

Enhancement Medical received a warning letter for failing to document supplier evaluations related to production of the Expression intranasal splint.

The Wauwatosa, Wisc., company’s procedures require a new vendor qualification form for potential suppliers, contractors and consultants. However, such a form did not exist for a contract manufacturer, contract testing facility, stem sterilizer or raw material supplier for hyaluronic acid, according to the June 4 warning letter posted online.

Enhancement had not performed an internal audit since it began operations in 2012, the letter says. The company’s procedure calls for such audits on a “routine basis.”
The FDA also cited Enhancement for failing to submit a report for a product removal. “Your firm made a decision in August 2013 to contact customers and exchange product with a lower gel weight that correlated with a significant increase in complaints of excessive swelling and/or pain experienced by patients,” the letter says.

Another citation notes the company does not test finished product to ensure that a requirement for a concentration specification is met. Enhancement lacks a host of written corrective and preventive action requirements, including ones for investigating the cause of nonconformities, verifying and validating CAPAs and submitting relevant information to management.

Meanwhile, Enhancement “routinely closes complaint records” without evaluating them for reportability, the letter says. Examples include complaints about:

  • A patient with hard nodules after injection of the product. “The adverse event form indicates Vitrase was administered without resolving the nodules,” the letter says. The complaint was closed without information on the patient’s outcome;
  • A patient with a “foreign body delayed reaction and nodule under the eye.” The adverse event form indicates prednisone was administered and a follow-up was set for 30 days. However, there is no evidence of a follow-up and the complaint was closed; and
  • A patient with “extreme swelling” after injection of Expression. The complaint was closed without additional information on the patient’s outcome.

The letter goes on to note that Enhancement did not process complaints in a timely manner and did not complete separate complaint records for complaints on multiple lots or multiple patients. Additional citations stemming from the Dec. 16, 2013, through Jan. 15 inspection related to medical device reporting.

Enhancement did not respond to a request for comment by press time.

Devicemakers are outsourcing more and more of their critical operations and materials, trying to wring out costs and improve their profitability. The unintended consequence? A much, much greater risk of supplier control violations. Prevent these violations by purchasing Device Supplier Controls today!

Medical Devices Inspections and Audits

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

  • Purple_Approved_Stamp.gif

    Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

  • Triple Vaccine, needles

    Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing